Q2 EPS Estimate for Avadel Pharmaceuticals Lifted by Analyst

Avadel Pharmaceuticals plc (NASDAQ:AVDL) – Stock analysts at Leerink Partnrs upped their Q2 2025 EPS estimates for shares of Avadel Pharmaceuticals in a report issued on Wednesday, May 7th. Leerink Partnrs analyst M. Goodman now forecasts that the company will post earnings per share of $0.00 for the quarter, up from their prior estimate of ($0.04). The consensus estimate for Avadel Pharmaceuticals’ current full-year earnings is ($0.51) per share. Leerink Partnrs also issued estimates for Avadel Pharmaceuticals’ FY2025 earnings at $0.10 EPS, FY2026 earnings at $0.75 EPS, FY2027 earnings at $1.35 EPS and FY2028 earnings at $1.70 EPS.

Several other analysts have also recently weighed in on AVDL. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Avadel Pharmaceuticals in a research note on Tuesday, February 11th. They issued a “buy” rating and a $12.00 price objective for the company. HC Wainwright reiterated a “buy” rating and issued a $21.00 price objective on shares of Avadel Pharmaceuticals in a research note on Tuesday, March 4th. UBS Group dropped their price objective on shares of Avadel Pharmaceuticals from $22.00 to $14.00 and set a “buy” rating for the company in a research note on Monday, January 13th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $19.00 price objective on shares of Avadel Pharmaceuticals in a research note on Thursday, May 8th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $19.43.

Avadel Pharmaceuticals Stock Up 2.1%

Shares of Avadel Pharmaceuticals stock opened at $9.59 on Monday. Avadel Pharmaceuticals has a twelve month low of $6.38 and a twelve month high of $17.51. The company has a 50-day simple moving average of $8.15 and a two-hundred day simple moving average of $9.43. The stock has a market capitalization of $926.67 million, a price-to-earnings ratio of -12.14 and a beta of 1.40.

Avadel Pharmaceuticals (NASDAQ:AVDL) last posted its earnings results on Wednesday, May 7th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.02. Avadel Pharmaceuticals had a negative net margin of 52.53% and a negative return on equity of 93.34%. The company had revenue of $52.51 million during the quarter, compared to analysts’ expectations of $50.57 million. During the same quarter last year, the company posted ($0.30) EPS. Avadel Pharmaceuticals’s quarterly revenue was up 93.2% compared to the same quarter last year.

Hedge Funds Weigh In On Avadel Pharmaceuticals

Several hedge funds have recently bought and sold shares of the company. Janus Henderson Group PLC increased its holdings in Avadel Pharmaceuticals by 5.7% in the 4th quarter. Janus Henderson Group PLC now owns 14,080,219 shares of the company’s stock valued at $148,117,000 after buying an additional 753,332 shares during the period. Two Seas Capital LP increased its holdings in Avadel Pharmaceuticals by 90.6% in the 4th quarter. Two Seas Capital LP now owns 4,296,449 shares of the company’s stock valued at $45,156,000 after buying an additional 2,042,669 shares during the period. Braidwell LP increased its holdings in Avadel Pharmaceuticals by 21.2% in the 4th quarter. Braidwell LP now owns 4,105,726 shares of the company’s stock valued at $43,151,000 after buying an additional 716,787 shares during the period. Vanguard Group Inc. grew its holdings in shares of Avadel Pharmaceuticals by 2.3% during the 4th quarter. Vanguard Group Inc. now owns 3,953,247 shares of the company’s stock valued at $41,549,000 after purchasing an additional 90,147 shares during the last quarter. Finally, Wealth Effects LLC grew its holdings in shares of Avadel Pharmaceuticals by 1.1% during the 1st quarter. Wealth Effects LLC now owns 2,369,122 shares of the company’s stock valued at $18,550,000 after purchasing an additional 24,992 shares during the last quarter. 69.19% of the stock is owned by institutional investors.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.